Onyx Pharmaceuticals Inc. and partner Bayer ended a late-stage study of its drug Nexavar in skin cancer patient because the drug was not working to improve patients' overall survival rate. The companies said an independent data monitoring committee concluded the drug would not meet its treatment goal of improved overall survival in patients.